Neuraly develops new drugs aimed at treating neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

Neuraly

Neuraly Inc. | 1,217 followers on LinkedIn. We discover and develop revolutionary treatments for neurodegenerative diseases | Neuraly is a clinical-stage company whose mission is to discover and develop scientific discoveries in neurology into revolutionary new drugs that can radically improve and prolong the lives of people suffering from the devastating consequences of diseases such as Parkinson’s disease (PD), Alzheimer’s disease (AD) and other neurodegenerative disorders. The company is leveraging a deep understanding of the role of glia biology in neuroinflammation and neuroprotection in advancing a risk-diversified product portfolio for PD and AD.

Co-founder and Chief Scientific Officer at Neuraly

Viktor Roschke

Exec. Director, Bioanalytical Development at Neuraly, Inc.

Svetlana Sosnovtseva

Founder and CEO at D&D Pharmatech

Seulki Lee

R&D Program Manager at Neuraly Inc

Taylor Lee

Neuraly Inc.

NEUR

COM:NEURALYMED

Neuraly